دورية أكاديمية
Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes.
العنوان: | Resveratrol and inflammation: Challenges in translating pre-clinical findings to improved patient outcomes. |
---|---|
المؤلفون: | Poulsen MM; Department of Endocrinology and Internal Medicine, MEA, Aarhus University Hospital and Institute of Clinical Medicine, Aarhus University, Denmark. Electronic address: mmp@ki.au.dk., Fjeldborg K; Department of Endocrinology and Internal Medicine, MEA, Aarhus University Hospital and Institute of Clinical Medicine, Aarhus University, Denmark., Ornstrup MJ; Department of Endocrinology and Internal Medicine, MEA, Aarhus University Hospital and Institute of Clinical Medicine, Aarhus University, Denmark., Kjær TN; Department of Endocrinology and Internal Medicine, MEA, Aarhus University Hospital and Institute of Clinical Medicine, Aarhus University, Denmark., Nøhr MK; Department of Endocrinology and Internal Medicine, MEA, Aarhus University Hospital and Institute of Clinical Medicine, Aarhus University, Denmark., Pedersen SB; Department of Endocrinology and Internal Medicine, MEA, Aarhus University Hospital and Institute of Clinical Medicine, Aarhus University, Denmark. |
المصدر: | Biochimica et biophysica acta [Biochim Biophys Acta] 2015 Jun; Vol. 1852 (6), pp. 1124-36. Date of Electronic Publication: 2015 Jan 09. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
اللغة: | English |
بيانات الدورية: | Publisher: Elsevier Pub. Co Country of Publication: Netherlands NLM ID: 0217513 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0006-3002 (Print) Linking ISSN: 00063002 NLM ISO Abbreviation: Biochim Biophys Acta Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Amsterdam : Elsevier Pub. Co. |
مواضيع طبية MeSH: | Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use , Obesity/*drug therapy , Stilbenes/*therapeutic use, Adipose Tissue/drug effects ; Adipose Tissue/metabolism ; Animals ; Anti-Inflammatory Agents, Non-Steroidal/pharmacology ; Clinical Trials as Topic ; Humans ; Inflammation/drug therapy ; Resveratrol ; Stilbenes/pharmacology ; Translational Research, Biomedical |
مستخلص: | Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes. (Copyright © 2015 Elsevier B.V. All rights reserved.) |
فهرسة مساهمة: | Keywords: Clinical trial; In vitro; In vivo; Inflammation; Metabolism; Resveratrol |
المشرفين على المادة: | 0 (Anti-Inflammatory Agents, Non-Steroidal) 0 (Stilbenes) Q369O8926L (Resveratrol) |
تواريخ الأحداث: | Date Created: 20150114 Date Completed: 20150827 Latest Revision: 20220408 |
رمز التحديث: | 20231215 |
DOI: | 10.1016/j.bbadis.2014.12.024 |
PMID: | 25583116 |
قاعدة البيانات: | MEDLINE |
تدمد: | 0006-3002 |
---|---|
DOI: | 10.1016/j.bbadis.2014.12.024 |